Literature DB >> 2213753

Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis.

N Takashina1, H Kondo, S Kashiwazaki.   

Abstract

Serum erythropoietin (EPO) was measured by radioimmunoassay in 67 patients with rheumatoid arthritis (RA). Twenty of these patients judged to have iron deficiency anemia, based on reduced serum ferritin levels, had higher serum EPO levels than did the 24 other anemic patients with normal or elevated serum ferritin levels. A significant negative correlation between serum EPO and hemoglobin concentrations was noted in the former group, but not in the latter. Human recombinant erythropoietin (r-EPO) was administered to 6 anemic patients with RA, resulting in improvement of anemia in 4 patients, 2 of whom showed no change in RA activity. These findings suggest a suppressed serum EPO response ot anemia and the effectiveness of r-EPO in treating anemia associated with RA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213753

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  Study of erythropoietin in treatment of anaemia in patients with rheumatoid arthritis.

Authors:  E A Murphy; A L Bell; J Wojtulewski; M Brzeski; R Madhok; H A Capell
Journal:  BMJ       Date:  1994-11-19

2.  Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin.

Authors:  B Gudbjörnsson; R Hällgren; L Wide; G Birgegård
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

3.  Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages.

Authors:  M A Smith; S M Knight; P J Maddison; J G Smith
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

4.  Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.

Authors:  H R Peeters; M Jongen-Lavrencic; G Vreugdenhil; A J Swaak
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

Review 5.  [Preoperative anemia in patients with rheumatic diseases].

Authors:  Lena Böhm; Marc Schmalzing; Patrick Meybohm
Journal:  Z Rheumatol       Date:  2022-01-28       Impact factor: 1.372

Review 6.  Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez; Ivan Solà; Daniel Simancas-Racines
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

7.  Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.

Authors:  Misato Hashizume; Yasushi Uchiyama; Naoto Horai; Naohisa Tomosugi; Masahiko Mihara
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

8.  Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis.

Authors:  G Vreugdenhil; B Manger; C Nieuwenhuizen; R A Feelders; H G van Eijk; A J Swaak
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

Review 9.  Inadequate erythropoietin response to anemia: definition and clinical relevance.

Authors:  G Barosi
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

10.  miR663 Prevents Epo Inhibition Caused by TNF-Alpha in Normoxia and Hypoxia.

Authors:  Mete Ozkurt; Thomas Hellwig-Bürgel; Reinhard Depping; Selda Kadabere; Rumeysa Ozyurt; Abdullah Karadag; Nilüfer Erkasap
Journal:  Int J Endocrinol       Date:  2021-07-27       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.